These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
608 related articles for article (PubMed ID: 31110217)
1. CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia. Pan J; Niu Q; Deng B; Liu S; Wu T; Gao Z; Liu Z; Zhang Y; Qu X; Zhang Y; Liu S; Ling Z; Lin Y; Zhao Y; Song Y; Tan X; Zhang Y; Li Z; Yin Z; Chen B; Yu X; Yan J; Zheng Q; Zhou X; Gao J; Chang AH; Feng X; Tong C Leukemia; 2019 Dec; 33(12):2854-2866. PubMed ID: 31110217 [TBL] [Abstract][Full Text] [Related]
2. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation. Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422 [TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia. Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493 [TBL] [Abstract][Full Text] [Related]
4. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report. Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L Front Immunol; 2021; 12():728962. PubMed ID: 34691036 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of co-administration of CD19 and CD22 CAR-T cells in children with B-ALL relapse after CD19 CAR-T therapy. Li W; Ding L; Shi W; Wan X; Yang X; Yang J; Wang T; Song L; Wang X; Ma Y; Luo C; Tang J; Gu L; Chen J; Lu J; Tang Y; Li B J Transl Med; 2023 Mar; 21(1):213. PubMed ID: 36949487 [TBL] [Abstract][Full Text] [Related]
6. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811 [TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of TCF3-HLF-positive Childhood B-ALL with Chimeric Antigen Receptor T-Cell Therapy. Wang T; Wan X; Yang F; Shi W; Liu R; Ding L; Tang Y; Luo C; Yang X; Ma Y; Wang X; Liang H; Li B; Lu J; Chen J Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):386-392. PubMed ID: 33640284 [TBL] [Abstract][Full Text] [Related]
8. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. Dai H; Wu Z; Jia H; Tong C; Guo Y; Ti D; Han X; Liu Y; Zhang W; Wang C; Zhang Y; Chen M; Yang Q; Wang Y; Han W J Hematol Oncol; 2020 Apr; 13(1):30. PubMed ID: 32245502 [TBL] [Abstract][Full Text] [Related]
9. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832 [TBL] [Abstract][Full Text] [Related]
10. Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study. Pan J; Tang K; Luo Y; Seery S; Tan Y; Deng B; Liu F; Xu X; Ling Z; Song W; Xu J; Duan J; Wang Z; Li C; Wang K; Zhang Y; Yu X; Zheng Q; Zhao L; Zhang J; Chang AH; Feng X Lancet Oncol; 2023 Nov; 24(11):1229-1241. PubMed ID: 37863088 [TBL] [Abstract][Full Text] [Related]
11. CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: Phase 1b results. Schultz LM; Jeyakumar N; Kramer AM; Sahaf B; Srinagesh H; Shiraz P; Agarwal N; Hamilton M; Erickson C; Jacobs A; Moon J; Baggott C; Arai S; Bharadwaj S; Johnston LJ; Liedtke M; Lowsky R; Meyer E; Negrin R; Rezvani A; Shizuru J; Sidana S; Egeler E; Mavroukakis S; Tunuguntla R; Gkitsas-Long N; Retherford A; Brown AK; Gramstrap-Petersen AL; Ibañez RM; Feldman SA; Miklos DB; Mackall CL; Davis KL; Frank M; Ramakrishna S; Muffly L Leukemia; 2024 May; 38(5):963-968. PubMed ID: 38491306 [TBL] [Abstract][Full Text] [Related]
12. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial. Shah NN; Highfill SL; Shalabi H; Yates B; Jin J; Wolters PL; Ombrello A; Steinberg SM; Martin S; Delbrook C; Hoffman L; Little L; Ponduri A; Qin H; Qureshi H; Dulau-Florea A; Salem D; Wang HW; Yuan C; Stetler-Stevenson M; Panch S; Tran M; Mackall CL; Stroncek DF; Fry TJ J Clin Oncol; 2020 Jun; 38(17):1938-1950. PubMed ID: 32286905 [TBL] [Abstract][Full Text] [Related]
13. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Cordoba S; Onuoha S; Thomas S; Pignataro DS; Hough R; Ghorashian S; Vora A; Bonney D; Veys P; Rao K; Lucchini G; Chiesa R; Chu J; Clark L; Fung MM; Smith K; Peticone C; Al-Hajj M; Baldan V; Ferrari M; Srivastava S; Jha R; Arce Vargas F; Duffy K; Day W; Virgo P; Wheeler L; Hancock J; Farzaneh F; Domning S; Zhang Y; Khokhar NZ; Peddareddigari VGR; Wynn R; Pule M; Amrolia PJ Nat Med; 2021 Oct; 27(10):1797-1805. PubMed ID: 34642489 [TBL] [Abstract][Full Text] [Related]
14. Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Liu S; Zhang X; Dai H; Cui W; Yin J; Li Z; Yang X; Yang C; Xue S; Qiu H; Miao M; Chen S; Jin Z; Fu C; Li C; Sun A; Han Y; Wang Y; Yu L; Wu D; Cui Q; Tang X Blood Cancer J; 2023 Apr; 13(1):60. PubMed ID: 37095120 [TBL] [Abstract][Full Text] [Related]
15. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia. Zhang X; Yang J; Li J; Li W; Song D; Lu XA; Wu F; Li J; Chen D; Li X; Xu Z; Liu S; Li Z; Ying K; Lu P Cancer Immunol Immunother; 2022 Mar; 71(3):689-703. PubMed ID: 34365516 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis. Willyanto SE; Alimsjah YA; Tanjaya K; Tuekprakhon A; Pawestri AR Ann Med; 2024 Dec; 56(1):2349796. PubMed ID: 38738799 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract. Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474 [TBL] [Abstract][Full Text] [Related]
18. Coadministration of CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell Acute Lymphoblastic Leukemia: A Single-Arm, Multicenter, Phase II Trial. Wang T; Tang Y; Cai J; Wan X; Hu S; Lu X; Xie Z; Qiao X; Jiang H; Shao J; Yang F; Ren H; Cao Q; Qian J; Zhang J; An K; Wang J; Luo C; Liang H; Miao Y; Ma Y; Wang X; Ding L; Song L; He H; Shi W; Xiao P; Yang X; Yang J; Li W; Zhu Y; Wang N; Gu L; Chen Q; Tang J; Yang JJ; Cheng C; Leung W; Chen J; Lu J; Li B; Pui CH J Clin Oncol; 2023 Mar; 41(9):1670-1683. PubMed ID: 36346962 [TBL] [Abstract][Full Text] [Related]
19. Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia. Ceppi F; Gardner RA Cancer J; 2019; 25(3):191-198. PubMed ID: 31135526 [TBL] [Abstract][Full Text] [Related]
20. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]